The DJBL represents a novel, reversible intervention for managing obesity and T2DM, addressing a significant unmet need in the market for patients who have not succeeded with traditional weight loss methods. Given the rising prevalence of obesity and diabetes globally, this device could capture a substantial share of the weight loss and diabetes management market. The competitive landscape includes traditional bariatric surgeries and pharmacological interventions, but DJBL's non-invasive nature may offer a distinct advantage. Diligence considerations should focus on long-term efficacy, safety data, and potential regulatory pathways for commercialization.